📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-18 17:16
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
22 announcements match the current filters (relevance ≥ 5).
Q1 Revenue up 51% YoY to ₹392.7 Cr; EBITDA up 39% to ₹91.7 Cr with ARPOB at ₹34,758
Yatharth reported a 51% YoY revenue growth in Q1 to ₹392.7 Cr (INR 3,927 million) and a 39% YoY increase in EBITDA to ₹91.7 Cr, driven by mature units and rapid scaling of new hospitals. Newer hospitals contributed 27% to total revenue, with Faridabad Sector 20 achieving EBITDA breakeven within 9 months and Agra delivering 20%+ EBITDA margins. Group ARPOB rose 7% YoY to an all-time high of ₹34,758, with premium NCR facilities crossing the ₹50,000 mark. The company currently operates 2,555 beds and reiterated its roadmap to reach 5,000 beds over the next few years, alongside declaring a maiden 5% interim dividend.
Confidence: HIGH
What changedYatharth published its Q1FY27 earnings call transcript highlighting record quarterly revenue, rapid acquisition turnaround, and plans for network expansion.
Why it mattersDemonstrates successful integration of acquired hospital assets, high ARPOB expansion via advanced specialties (oncology, robotics), and consistent operating leverage.
Q1 Revenue: INR 3,927 millionQ1 EBITDA: INR 917 millionQ1 PAT: INR 454 millionGroup ARPOB: INR 34,758Current Bed Capacity: 2,555 beds
📅 Short termRobust execution and improving profitability across acquired hospitals provide strong fundamental support.
📈 Long termDoubling bed capacity to 5,000 beds and scaling high-margin oncology and robotics offerings provide strong multi-year compounding potential.
⚠ Risk flags
- Geographic concentration in Delhi-NCR and North India
- Execution and clinical talent retention risks associated with rapid bed additions
Key Highlights
Q1 revenue increased 51% YoY to INR 3,927 million; consolidated EBITDA reached INR 917 million (23.3% margin, adjusted 28.1%).
Consolidated PAT reached INR 454 million with cash profit growing 32% YoY.
Blended ARPOB hit an all-time high of INR 34,758, led by Noida Extension and New Delhi exceeding INR 50,000.
Newer hospitals contributed INR 1,067 million (27% of revenue mix) as turnaround playbook delivered fast breakevens.
Operational bed network expanded to 2,555 beds, targeting over 3,200 beds near term and 5,000 beds within 3 years.
👀 What to Watch
Track the commercial launch timeline of the 250-bed Gurugram hospital scheduled for Q1 of the next fiscal, as well as occupancy gains in Noida Extension and brownfield expansions.
51% YoY Revenue Growth in Q1 FY27; Faridabad Unit Achieves EBITDA Breakeven
Yatharth Hospital reported a robust Q1 FY27 with revenue growing 51% YoY to ₹392.7 cr, significantly higher than the previous year's quarterly average. Operational efficiency improved as occupancy reached 68% (up from 65% YoY) and ARPOB increased 7% YoY to ₹34,758. Notably, the Faridabad Sector-20 unit achieved EBITDA breakeven within just 9 months, while the Agra unit delivered >20% margins in its first full quarter. The company also declared its first interim dividend of 5% of face value.
Confidence: HIGH
What changedThe company has successfully integrated recent acquisitions, with new units like Agra and Faridabad reaching profitability milestones faster than industry averages.
Why it mattersThe rapid turnaround of new units validates the company's acquisition playbook and supports its high P/E valuation (49.2) by demonstrating scalable growth in the Delhi-NCR region.
Q1 FY27 Revenue: ₹392.7 crRevenue vs TTM Revenue: 32.7%ARPOB: ₹34,758Adjusted EBITDA Margin: 28.1%Occupancy Rate: 68%Interim Dividend: 5% of Face Value
📅 Short termThe stock is likely to react positively to the strong top-line growth and the achievement of EBITDA breakeven in the Faridabad unit.
📈 Long termThe expansion to 2,800+ beds and entry into high-ARPOB segments like robotics and oncology provide a structural growth runway for the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Geographic concentration in North India
- High attrition risk of specialized medical professionals
- Ramp-up risks for the upcoming Gurugram facility
Key Highlights
Revenue increased 51% YoY to ₹392.7 cr, representing ~33% of the total TTM revenue in a single quarter.
Adjusted EBITDA margin (excluding ramp-up losses) stood at 28.1%, compared to the consolidated 23.3%.
Bed occupancy improved to 68% from 65% in Q1 FY26, despite a significant increase in operational beds.
New hospitals (Faridabad, Delhi, Agra) now contribute 27% to the total revenue mix.
Total bed capacity reached 2,800+, including the 250-bed Gurugram facility expected by Q1 FY2028.
👀 What to Watch
Watch for the operational commencement of the Gurugram facility in Q1 FY2028 and the ability to maintain the 28% adjusted EBITDA margin as newer units mature.
₹0.50 Dividend Declared and 2.5 Lakh Share ESOP Scheme Approved by Yatharth Hospital
Yatharth Hospital reported a 34.9% YoY increase in standalone revenue for Q1 FY27, reaching ₹176.3 Cr compared to ₹130.7 Cr in the previous year. The Board declared a first interim dividend of ₹0.50 per share (5% of face value), with a total payout of ₹4.82 Cr. Additionally, a new ESOP Scheme 2026 was approved, covering 250,000 equity shares to incentivize and retain key employees. While revenue growth was robust, standalone PAT grew more modestly at 3.9% YoY to ₹28.17 Cr.
Confidence: HIGH
What changedThe company has reported its Q1 FY27 financial performance, initiated its first dividend for the fiscal year, and introduced a new employee stock option framework.
Why it mattersThe strong revenue growth validates the company's expansion strategy in North India, while the ESOP scheme is a critical tool for retaining specialized medical professionals in a high-attrition industry.
Q1 Standalone Revenue: ₹176.3 CrYoY Revenue Growth: 34.9%Interim Dividend: ₹0.50 per shareDividend Payout vs TTM PAT: ~2.8%ESOP Shares: 2,50,000 unitsStandalone PAT: ₹28.17 Cr
📅 Short termThe stock may see positive sentiment due to the dividend declaration and strong top-line growth, with immediate focus on the August 14 record date.
📈 Long termThe ESOP scheme supports long-term talent retention, which is vital for the company's goal of reaching 3,000 beds and increasing ARPOB through specialized treatments.
⚠ Risk flags
- PAT growth (3.9%) significantly lagging revenue growth (34.9%) suggesting margin pressure
- Potential equity dilution from the new ESOP scheme
Key Highlights
Standalone revenue from operations grew 34.9% YoY to ₹176.3 Cr in Q1 FY27.
Interim dividend of ₹0.50 per share declared with a record date of August 14, 2026.
Approved ESOP 2026 scheme involving 250,000 equity shares, representing approximately 0.26% of total equity.
Standalone Profit After Tax (PAT) for the quarter stood at ₹28.17 Cr vs ₹27.12 Cr YoY.
Total dividend payout for this interim period amounts to ₹4.82 Cr.
👀 What to Watch
Investors should monitor the company's ability to translate high revenue growth into better bottom-line margins, as PAT growth lagged revenue this quarter. Watch for the upcoming record date of August 14, 2026, for dividend eligibility.
Rs 0.50 Interim Dividend: Yatharth Hospital Sets August 14, 2026, as Record Date
Yatharth Hospital has declared its first interim dividend for FY 2026-27 at Rs 0.50 per equity share (5% of face value). The Board of Directors fixed August 14, 2026, as the record date to determine shareholder eligibility. The total paid-up share capital involved is Rs 96.35 crore. Based on the current stock price of Rs 865.7, this specific payout represents a nominal yield of approximately 0.06%.
Confidence: HIGH
What changedThe company has officially scheduled the record date and confirmed the quantum for its first interim dividend of the 2026-27 financial year.
Why it mattersWhile the dividend amount is small relative to the share price, it signals a commitment to shareholder returns alongside the company's aggressive 30% growth strategy and geographic expansion.
Dividend per share: Rs 0.50Dividend as % of Face Value: 5%Record Date: August 14, 2026TTM EPS: Rs 18.28Dividend Yield (approx): 0.06%
📅 Short termThe stock may see a minor price adjustment on the ex-dividend date (typically one business day before the record date) reflecting the Rs 0.50 payout.
📈 Long termLimited structural significance; the company's long-term value is tied to its ability to scale ARPOB (currently Rs 25,080) and integrate new acquisitions in North India.
Key Highlights
Interim dividend declared at Rs 0.50 per equity share of face value Rs 10 each.
Record date for determining entitlement is fixed for Friday, August 14, 2026.
Dividend payment will be processed within 30 days from the declaration date (August 10, 2026).
Total paid-up share capital of the company stands at Rs 96,35,43,570.00.
The dividend is subject to Tax Deduction at Source (TDS) as per the Income Tax Act, 1961.
👀 What to Watch
Investors should note the record date of August 14 to ensure they hold shares in their demat accounts by this date to receive the payout. The focus should remain on the company's execution of its 3,000-bed capacity target rather than this minor dividend yield.
₹0.50 Interim Dividend and 34.8% YoY Revenue Growth for Yatharth Hospital in Q1 FY27
Yatharth Hospital has declared its first interim dividend of ₹0.50 per share (5% of face value) for FY27, amounting to a total payout of ₹4.82 Cr. The company reported standalone revenue of ₹176.31 Cr for Q1 FY27, representing a 34.8% growth compared to ₹130.72 Cr in the same quarter last year. Additionally, the board approved a new ESOP scheme for 250,000 shares to incentivize employees. The record date for the dividend is fixed for August 14, 2026.
Confidence: HIGH
What changedThe company has initiated its dividend cycle for FY27 and reported strong double-digit revenue growth for the first quarter.
Why it mattersThe dividend payout, though small relative to PAT (~2.8%), signals management's confidence in cash flows, while the revenue growth validates the company's expansion strategy in the North India market.
Interim Dividend: ₹0.50 per shareTotal Dividend Payout: ₹4.82 CrDividend vs TTM PAT: ~2.8%Q1 Standalone Revenue Growth (YoY): 34.8%ESOP Shares: 2,50,000 unitsRecord Date: August 14, 2026
📅 Short termThe stock may see mild positive sentiment leading up to the record date of August 14, supported by the revenue growth figures.
📈 Long termThe company's ability to maintain high growth rates while expanding its bed capacity toward the 3,000-bed target remains the primary long-term value driver.
⚠ Risk flags
- Geographic concentration in North India
- Potential equity dilution from the new ESOP scheme
Key Highlights
Declared first interim dividend of ₹0.50 per equity share for FY27
Total dividend payout quantified at ₹4,81,77,178.50
Standalone revenue from operations increased 34.8% YoY to ₹176.31 Cr
Record date for dividend entitlement set for August 14, 2026
Approved ESOP 2026 scheme covering 250,000 equity shares
👀 What to Watch
Investors should monitor the sustainability of the 34% revenue growth and the impact of the new ESOP scheme on future earnings per share (EPS) dilution.
51% YoY Revenue Growth in Q1 FY27; Faridabad Unit Hits EBITDA Breakeven
Yatharth Hospital reported a robust Q1 FY27 with revenue surging 51% YoY to Rs 392.7 Cr, significantly outpacing its historical growth rates. While consolidated EBITDA margins were 23.3%, the adjusted margin (excluding ramp-up losses from new units) reached a strong 28.1%. Operational efficiency improved with occupancy rising to 68% and ARPOB increasing 7% YoY to Rs 34,758. Notably, the Faridabad Sector-20 unit achieved EBITDA breakeven within just 9 months of operation, and the company declared its first interim dividend of 5% of face value.
Confidence: HIGH
What changedThe company has demonstrated a successful 'acquisition playbook' with the Agra unit turning profitable (>20% margin) in its first full quarter and Faridabad hitting breakeven ahead of typical industry timelines.
Why it mattersThe strong performance validates Yatharth's strategy of aggressive inorganic expansion in North India and its ability to drive higher-value clinical work (oncology/robotics), which is reflected in the rising ARPOB.
Q1 Revenue: Rs 392.7 CrRevenue vs TTM Revenue: 32.7%Adjusted EBITDA Margin: 28.1%ARPOB: Rs 34,758Occupancy Rate: 68%Interim Dividend: 5% of Face Value
📅 Short termThe stock is likely to react positively to the strong top-line growth and the rapid turnaround of newly acquired units, which reduces concerns over near-term margin dilution.
📈 Long termThe company is structurally positioned for growth with a clear path to 3,000 beds and a proven ability to integrate acquisitions, though geographic concentration in Delhi-NCR remains a factor to watch.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Ramp-up risks for newer hospitals
- Geographic concentration in North India
- High dependency on specialized medical professionals
Key Highlights
Revenue grew 51% YoY to Rs 392.7 Cr, representing approximately 33% of the total TTM revenue in a single quarter
Adjusted EBITDA margin stood at 28.1% after excluding ramp-up losses from Model Town and Faridabad units
Faridabad Sector-20 unit achieved EBITDA breakeven in a record 9 months
ARPOB increased to Rs 34,758, a 7% growth compared to Q1 FY26
Total bed capacity reached 2,800+ including the 250-bed Gurugram facility expected by Q1 FY2028
👀 What to Watch
Investors should monitor the margin trajectory as the Model Town and Faridabad units scale up, potentially closing the gap between consolidated (23.3%) and adjusted (28.1%) margins. Track the execution timeline of the 250-bed Gurugram hospital project slated for 2028.
51% YoY Revenue Growth in Q1FY27; Yatharth Declares Maiden Interim Dividend
Yatharth Hospital reported a strong Q1FY27 with revenue surging 51% YoY to 392.7 cr, significantly outpacing its TTM growth trends. EBITDA grew 39% YoY to 91.7 cr, though margins compressed to 23.3% from 25.4% due to the ramp-up of new acquisitions. A key highlight is the Faridabad Sector-20 unit achieving EBITDA breakeven in just 9 months, while the board declared its first-ever interim dividend at 5% of face value. PAT growth was relatively muted at 8% YoY ( 45.4 cr) due to increased depreciation from recent capacity additions.
Confidence: HIGH
What changedYatharth has successfully integrated recent acquisitions, with new units now contributing over a quarter of total revenue and one achieving breakeven ahead of schedule.
Why it mattersThe results validate the company's acquisition-led growth strategy and its ability to quickly turn around new assets, supporting its long-term target of reaching ~3,250 beds.
Q1FY27 Revenue: 392.7 crRevenue vs TTM Revenue: 32.7%EBITDA Margin: 23.3%Adjusted EBITDA Margin: 28.1%New Hospital Revenue Share: 27%Interim Dividend: 5% of Face Value
📅 Short termThe stock is likely to react positively to the record revenue growth and the surprise maiden dividend, reflecting management's confidence in cash flows.
📈 Long termThe company is successfully scaling its hub-and-spoke model in North India; sustained ARPOB growth and bed additions provide a clear path for multi-year compounding.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Margin dilution during the initial ramp-up phase of new hospitals
- High depreciation from aggressive capacity expansion impacting net profit growth
Key Highlights
Revenue reached a record 392.7 cr in Q1FY27, up 51% YoY and 15% QoQ.
New hospitals contributed 106.7 cr, representing 27% of total group revenue.
Group ARPOB increased 7% YoY to 34,758, with premium NCR hospitals reaching the 50,000 mark.
Faridabad Sector-20 unit achieved EBITDA breakeven within a record 9 months of operations.
Adjusted EBITDA margin (excluding new unit ramp-up impacts) stood strong at 28.1%.
👀 What to Watch
Monitor the occupancy levels and margin improvement in the Agra and Faridabad units as they mature, and track the progress of the upcoming Gurugram hospital expansion.
Yatharth Q1 Standalone Revenue Up 35% YoY to ₹176 Cr; ₹0.50 Interim Dividend Declared
Yatharth Hospital reported a strong 34.9% YoY growth in standalone revenue from operations, reaching ₹176.31 Cr for Q1 FY27. However, standalone net profit grew only 3.9% YoY to ₹28.17 Cr, primarily due to a sharp rise in finance costs to ₹5.31 Cr (vs ₹0.16 Cr YoY) and doubled depreciation expenses. The board declared an interim dividend of ₹0.50 per share (5% of face value) with a record date of August 14, 2026. Additionally, a new ESOP scheme for 250,000 shares was approved to incentivize employees.
Confidence: HIGH
What changedThe company has reported its first-quarter results for FY27, initiated an interim dividend, and established a new employee stock option pool.
Why it mattersThe strong top-line growth confirms the company's successful scale-up in the North India market, though the lag in profit growth highlights the cost of aggressive expansion (higher interest and depreciation).
Q1 Standalone Revenue: ₹176.31 CrYoY Revenue Growth: 34.9%Interim Dividend: ₹0.50 per shareFinance Costs (Q1 FY27): ₹5.31 CrESOP Pool Size: 2,50,000 sharesDividend Record Date: August 14, 2026
📅 Short termThe stock may see positive sentiment from the robust revenue growth and dividend declaration, though the surge in finance costs might temper gains.
📈 Long termThe company is executing its strategy to reach 3,000 beds; long-term value depends on improving occupancy and ARPOB at new units to offset expansion costs.
⚠ Risk flags
- Sharp increase in finance costs (up >30x YoY)
- Muted PAT growth relative to revenue
- Potential equity dilution from ESOPs
Key Highlights
Standalone Revenue from operations increased 34.9% YoY to ₹176.31 Cr from ₹130.72 Cr.
Interim dividend of ₹0.50 per share declared, involving a total payout of ₹4.82 Cr.
Finance costs surged significantly to ₹5.31 Cr in Q1 FY27 compared to ₹0.16 Cr in Q1 FY26.
Depreciation and amortisation expenses rose to ₹10.09 Cr from ₹4.69 Cr YoY.
Approved 'ESOP 2026' scheme covering 250,000 equity shares, subject to shareholder approval.
👀 What to Watch
Investors should monitor the consolidated results to assess the performance of recently acquired units in Faridabad and Agra, and track if the high finance costs are transitory due to expansion debt.
Yatharth Hospital Completes ₹100 Crore Acquisition of Gurugram Hospital Asset
Yatharth Hospital has successfully finalized the acquisition of a hospital asset located in Sector 40, Gurugram, from RNY Healthcare Services Private Limited. The total consideration of ₹100 Crores has been fully paid, and the transaction formalities were completed on June 12, 2026. The asset is now registered under AKS Medical & Research Centre Private Limited, which is a wholly-owned subsidiary of the company. This acquisition marks a significant step in the company's expansion strategy within the National Capital Region (NCR).
Key Highlights
Completed acquisition of hospital asset in Sector 40, Gurugram for ₹100 Crores.
Asset registered under wholly-owned subsidiary AKS Medical & Research Centre Private Limited.
Full payment of the ₹100 Crore consideration has been executed.
Transaction follows the initial acquisition announcement made on May 13, 2026.
👀 What to Watch
Investors should monitor the integration of this new asset and its impact on bed capacity and revenue growth in the upcoming quarters. This expansion into the Gurugram market is a positive indicator of the company's scaling capabilities.
Yatharth Hospital Q4 FY26 Revenue Jumps 47% YoY to INR 3,416 Mn; FY26 PAT Up 30%
Yatharth Hospital reported a robust 36% YoY revenue growth for FY26, reaching INR 12,072 million, driven by strong performance in existing units and rapid ramp-up of new facilities. The company's EBITDA for the full year rose 30% to INR 2,921 million, while Q4 occupancy reached 71%. Strategic expansions include a new Gurugram facility and the integration of the Agra hospital, which is already generating INR 7 crore in monthly revenue. With a net cash position of INR 1,160 million, the company is well-positioned to reach its target of 5,000 beds within the next three years.
Key Highlights
Consolidated FY26 revenue grew 36% YoY to INR 12,072 million with EBITDA margins at 24.2%.
Q4 FY26 ARPOB improved to INR 33,282, with Noida Extension hitting a record INR 47.8k.
New Delhi and Faridabad Sector 20 hospitals contributed 11% to Q4 revenue with superior payer mix.
Acquired a Gurugram hospital project for INR 100 crore, expected to be operational by April 2027.
Total bed capacity reached 3,200+ with a long-term target of 5,000 beds.
👀 What to Watch
Investors should view the strong ramp-up in new hospitals and the entry into the high-ARPOB Gurugram market as key growth catalysts. The company's ability to maintain a 98% cash conversion ratio provides significant financial flexibility for further brownfield expansions.
Yatharth Hospital Q4 FY26 Revenue Surges 47% YoY to ₹3,416 Mn; EBITDA Up 37%
Yatharth Hospital delivered a robust Q4 FY26 performance with revenue growing 47% YoY to ₹3,416 million, supported by strong traction in newer hospitals which now contribute 22% of total revenue. While reported EBITDA margins dipped to 23.4% due to ramp-up costs, the adjusted EBITDA margin remained high at 30.4%. The company continues its expansion momentum with a new 250-bed Gurugram facility set to open in early FY27. Operational efficiency improved as debtor days reduced to 112 and cash conversion reached 98%.
Key Highlights
Q4 FY26 Revenue grew 47% YoY to ₹3,416 Mn, while full-year FY26 revenue rose 36% to ₹12,072 Mn.
Adjusted EBITDA margin (excluding ramp-up losses) stood at 30.4%, with reported EBITDA up 37% YoY to ₹799 Mn.
Group ARPOB increased 5% YoY to ₹33,283, led by Noida Extension at ₹47.8k and Greater Noida at ₹40.3k.
Newer hospitals in Delhi, Faridabad, and Agra contributed ₹753 Mn, representing 22% of the Group's quarterly revenue.
Strong balance sheet management with a 98% cash conversion ratio and debtor days improving from 125 to 112.
👀 What to Watch
Investors should view the strong revenue growth and successful integration of new assets as a positive sign for long-term scalability. Monitor the upcoming Gurugram facility launch and the stabilization of margins as newer hospitals reach maturity.
Yatharth Hospital FY26 Revenue Up 30% to ₹5,919 Mn; Q4 PAT Rises 8.5% YoY
Yatharth Hospital reported a strong 29.6% growth in standalone revenue for FY26, reaching ₹5,918.84 million compared to ₹4,564.84 million in FY25. While top-line growth was robust, annual net profit growth was more modest at 8.8%, totaling ₹954.10 million, impacted by higher operational and finance costs. For Q4 FY26, revenue surged 45.6% YoY to ₹1,638.71 million, though PAT growth was limited to 8.5% YoY. The company's equity base strengthened significantly, with other equity rising to ₹15,232.24 million.
Key Highlights
Standalone Revenue for FY26 grew 29.6% YoY to ₹5,918.84 million.
Q4 FY26 Revenue increased significantly by 45.6% YoY to ₹1,638.71 million.
Annual Net Profit (PAT) for FY26 stood at ₹954.10 million, up 8.8% from ₹876.92 million.
Finance costs spiked to ₹57.31 million in FY26 from just ₹6.16 million in the previous year.
Depreciation and amortization expenses rose to ₹304.59 million in FY26 versus ₹186.63 million in FY25.
👀 What to Watch
Investors should monitor the company's ability to convert high revenue growth into better bottom-line margins as new capacities stabilize. The significant jump in depreciation and finance costs suggests recent capital expenditure which warrants a watch on occupancy rates.
Yatharth Hospital Shareholders Approve Creation of Security with 99.99% Majority
Shareholders of Yatharth Hospital have overwhelmingly approved a special resolution to create security by way of charge, mortgage, or hypothecation on company assets. The resolution, passed via postal ballot on May 12, 2026, received 99.99% votes in favor, representing approximately 6.74 crore shares. This approval under Section 180(1)(a) of the Companies Act allows the company to secure its borrowings against its assets, providing necessary flexibility for future capital requirements. Both promoters and institutional investors showed 100% support for the proposal.
Key Highlights
Special resolution passed with 99.99% of total votes in favor (6,74,23,350 votes).
100% support received from both Promoter Group and Public Institutional investors.
Enables the company to create charges or mortgages on assets to secure future borrowings.
Total votes polled represented 69.98% of the total outstanding shares of the company.
The resolution was passed as a Special Resolution through a remote e-voting process.
👀 What to Watch
This is a routine enabling resolution that allows the company to leverage its assets for future financing. Investors should monitor subsequent announcements regarding specific debt tie-ups or expansion plans that this security creation will support.
Yatharth Hospital Acquires 250-Bed Hospital in Gurugram for INR 100 Crores
Yatharth Hospital has announced the acquisition of an under-construction 250-bed hospital in Sector 40, Gurugram, for a consideration of approximately INR 100 crores. The company plans an additional capital outlay of INR 100 crores to complete the project and install medical equipment, bringing the total investment to INR 200 crores. This acquisition marks the group's entry into the lucrative Gurugram market, strategically located near high-income residential hubs and the IGI airport. The move increases the company's total announced bed capacity to approximately 3,250 beds.
Key Highlights
Acquisition of an under-construction 250-bed hospital in Sector 40, Gurugram for ~INR 100 crores
Additional ~INR 100 crores earmarked for project completion and medical equipment procurement
Total announced bed capacity for the group increases to ~3,250 beds
Strategic entry into the high-growth Gurugram healthcare market targeting domestic and international patients
Facility is located in a high-income catchment area with proximity to premium commercial districts
👀 What to Watch
This expansion into the high-margin Gurugram market is a significant growth lever; investors should monitor the project's completion timeline and its impact on overall ROCE.
Yatharth Hospital to Acquire 250-Bed Gurugram Asset for Rs 100 Crore
Yatharth Hospital has approved the acquisition of a hospital asset in Sector 40, Gurugram, from RNY Healthcare Services for a cash consideration of Rs 100 crore. The acquisition includes 1.30 acres of land and a building under construction with a potential capacity of approximately 250 beds. The company intends to spend an additional Rs 100 crore on capital expenditure and medical equipment to operationalize the facility. This strategic move is aimed at significantly strengthening the group's presence within the Delhi NCR healthcare market.
Key Highlights
Acquisition of 1.30 acres land and building in Gurugram for Rs 100 crore cash consideration
Potential addition of ~250 beds to the company's total capacity in the Delhi NCR region
Planned additional capex of Rs 100 crore for medical equipment and facility completion
Indicative timeline for completion of the acquisition is set at 45 days
Acquisition is being made on an 'as-is-where-is' basis from RNY Healthcare Services
👀 What to Watch
Investors should monitor the timely completion of the acquisition and the subsequent ramp-up of the Gurugram facility, as it represents a significant capacity expansion. The total investment of Rs 200 crore indicates a strong growth trajectory in a high-demand geography.
Yatharth Hospital Seeks Shareholder Nod to Create Security on Assets up to ₹1,000 Crores
Yatharth Hospital has initiated a postal ballot to seek shareholder approval for creating charges, mortgages, or hypothecations on its assets. The special resolution, under Section 180(1)(a) of the Companies Act, 2013, proposes a limit of ₹1,000 crores to secure various debt instruments. This authorization will allow the company to secure term loans, debentures, and other credit facilities from banks and financial institutions. The move provides the board with the necessary flexibility to leverage company assets for future growth and operational funding.
Key Highlights
Proposed limit for creation of security on movable and immovable assets is ₹1,000 crores.
Approval sought via special resolution under Section 180(1)(a) of the Companies Act, 2013.
Security to cover various instruments including Rupee loans, commercial papers, and foreign currency borrowings.
Remote e-voting period is scheduled from April 13, 2026, to May 12, 2026.
The resolution enables the board to secure both existing and future borrowings to support company undertakings.
👀 What to Watch
This is a standard enabling resolution that increases the company's capacity to secure debt for future requirements. Investors should monitor for subsequent announcements regarding specific expansion plans or capital expenditures that may utilize this ₹1,000 crore headroom.
Yatharth Hospital Q3 FY26 Revenue Surges 46% YoY to INR 321 Cr; New Units Scale Rapidly
Yatharth Hospital reported its highest-ever quarterly revenue of INR 3,205 million, marking a robust 46% YoY growth driven by existing facilities and a rapid scale-up of new hospitals in Delhi and Faridabad. The company achieved an adjusted EBITDA margin of 29.2% and a Net Profit of INR 431 million, up 41% YoY. Management highlighted that new facilities in Delhi and Faridabad Sector-20 contributed 9% to group revenue in their first full quarter with ARPOBs exceeding the group average. With the integration of the Agra hospital in February 2026 and a roadmap to reach 5,000 beds, the company maintains a strong growth trajectory.
Key Highlights
Consolidated revenue grew 46% YoY to INR 3,205 million, with existing hospitals growing 33% YoY.
New Delhi and Faridabad Sector-20 hospitals generated INR 279 million in their first full quarter of operations.
Group ARPOB increased 10% YoY to INR 33,744, with Noida Extension reaching a record INR 44,000.
Net Profit (PAT) increased 41% YoY to INR 431 million, while adjusted PAT surged 80% YoY.
Maintains a strong balance sheet with a net cash position of approximately INR 200 crores as of December 31, 2025.
👀 What to Watch
Investors should monitor the successful integration of the Agra facility and the company's progress toward reducing government business mix to below 30%. The rapid breakeven of new units and aggressive expansion plans make it a high-growth contender in the regional healthcare space.
Yatharth Hospital Q3 FY26: Revenue Jumps 46% to ₹320 Cr, PAT Rises 41% to ₹43 Cr
Yatharth Hospital delivered a strong performance in Q3 FY26, with revenue growing 46% YoY to ₹3,205 million and PAT increasing 41% to ₹431 million. Operational efficiency improved as occupancy reached 67% and ARPOB grew 10% to ₹33,744. The company successfully ramped up its new Delhi and Faridabad facilities, which contributed 9% to the total revenue. Additionally, the integration of the newly acquired 250-bed Agra hospital from February 2026 is expected to be immediately accretive to the bottom line.
Key Highlights
Revenue grew 46% YoY to ₹3,205 mn and EBITDA increased 35% YoY to ₹742 mn in Q3 FY26.
Adjusted EBITDA margin (excluding new hospital ramp-up losses) stood at a robust 29.2%.
Occupancy improved to 67% from 56% YoY, while ARPOB increased 10% YoY to ₹33,744.
New Delhi and Faridabad Sec-20 hospitals generated ₹279 mn revenue in their first full quarter of operations.
Integrated a 250-bed Agra hospital on Feb 1, 2026, acquired for ₹260 Cr to expand the UP footprint.
👀 What to Watch
The stock remains a strong growth play in the healthcare sector given its successful M&A execution and rapid ramp-up of new beds. Investors should monitor the margin trajectory as new hospitals reach optimal utilization.
Yatharth Hospital Q3 FY26: Revenue Surges 46% YoY to Rs 321 Cr, PAT Up 41%
Yatharth Hospital reported a robust performance for Q3 FY26, with revenue growing 46% YoY to Rs 3,205 million and PAT increasing 41% to Rs 431 million. The growth was significantly bolstered by newly operational hospitals in New Delhi and Faridabad, which contributed 9% of total revenue in their first full quarter. While reported EBITDA margins dipped to 23.2% due to initial ramp-up costs, the adjusted EBITDA margin stood at a strong 29.2%. The company also achieved a 10% YoY improvement in Group ARPOB, reaching Rs 33,744.
Key Highlights
Operating revenue grew 46% YoY to Rs 3,205 million, driven by a 33% growth in existing hospitals and new asset contributions.
New hospitals in New Delhi and Faridabad Sec-20 contributed Rs 279 million in revenue with 100% Cash/TPA payer mix.
Group ARPOB increased 10% YoY to Rs 33,744, with Noida Extension reaching a record high of Rs 44,000.
Adjusted EBITDA margin (excluding new hospital losses) stood at 29.2%, reflecting strong operating leverage.
Total bed capacity expanded to over 2,550 beds following the integration of the Agra facility in February 2026.
👀 What to Watch
Investors should note the company's exceptional ability to rapidly scale and turn around new acquisitions while maintaining high ARPOB growth. The stock remains a strong growth candidate in the healthcare sector given the successful integration of new assets and focus on high-margin payer mixes.
Yatharth Hospital Q3 Standalone Revenue Jumps 43% YoY to ₹158.1 Cr; Agra Hospital Acquired
Yatharth Hospital reported a robust 43% YoY growth in standalone revenue to ₹158.15 crore for Q3 FY26. While Net Profit grew 7.4% YoY to ₹23.89 crore, the company showed strong sequential momentum with PAT rising 15.7% QoQ. The company continues its aggressive expansion, acquiring a 150-bed hospital in Agra effective February 2026. Additionally, the release of provisional attachments by the Income Tax department on company assets provides significant regulatory relief.
Key Highlights
Standalone Revenue from operations grew 43% YoY to ₹1,581.5 million.
Standalone Profit After Tax (PAT) increased 7.4% YoY to ₹238.9 million.
Acquired Shantived Institute of Medical Sciences in Agra with 150 operational beds (expandable to 250).
Utilized ₹5,862.3 million of QIP proceeds for debt repayment, acquisitions, and medical equipment.
Income Tax department released provisional attachments on properties, bank deposits, and cash balances.
👀 What to Watch
Investors should view the strong revenue growth and inorganic expansion as positive indicators for long-term scale. Monitor the margin trajectory as the new Agra facility integrates and the pending tax appeal progresses.
